Follow Intellia Therapeutics to never miss an important update.
Intellia shared new data from seven presentations at a major medical meeting regarding lonvo-z, its treatment for hereditary angioedema. This disease causes severe and unpredictable swelling, and the latest results show that the one-time gene-editing treatment continues to improve patient lives by reducing those attacks.
This data is important because it strengthens the case for the treatment as it nears a March 2027 deadline for FDA approval. If approved, this would be the first-ever CRISPR therapy that works by editing genes directly inside a patient's body. These consistent results suggest the technology is reliable, which is the main thing the company needs to prove to move from a research lab to a business with its first selling product.
Source: GlobeNewsWire
After Intellia reported its November results, we updated our fair value and cut our quality score to 3.1. We have added the risk of volatility in the company's investment portfolio to what we track. We also added the decline in revenue from partners like Regeneron to our analysis of how the business pays for its research. We updated our projections to include the costs of hiring a new sales force ahead of the company's first potential product launch in early 2027.
Intellia reported a loss of 91 cents per share, which was wider than the 80 cents analysts expected. As a clinical-stage biotech, the company has almost no revenue and instead focuses on its cash pile, which it expects will last into 2028. This provides enough of a cushion to launch its first gene-editing therapy and continue trials for its heart disease programs.
The focus remains on March 10, 2027, the date the FDA will decide whether to approve lonvo-z for a rare swelling disorder. Management confirmed they are ready for a commercial launch if approved. While the quarterly loss was larger than expected, the business is hitting its clinical milestones, including finishing enrollment for a major trial in a rare nerve disease.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Intellia has finished signing up patients for its Phase 3 trial of nex-z, a CRISPR treatment for a rare genetic disease that causes nerve damage. This is a key step toward getting the drug approved, as it allows the company to begin the final stretch of data collection needed for an FDA filing.
While the company's first drug for a different condition is closer to market, nex-z is a larger part of the long-term value because it targets a broader group of patients. Finishing enrollment on schedule keeps the company on track to prove its gene-editing platform can work across multiple diseases, which is the core of why the business matters.
Source: GlobeNewsWire
After Intellia reported its August results, we raised our quality score to 3.9 out of 5 to reflect faster growth and improved risk management. We have added the cost of new genetic screening protocols for patients to our projections for the first commercial drug launch. We also added the $400 million debt facility to what we track, as it reduces the need for the company to sell more shares to raise cash. Our projections now include the specific dates the company expects to finish enrolling patients for its study on nerve damage.
Management has a long record of beating their own targets, but recent misses on both sales and profit suggest the business is becoming harder to forecast as it shifts toward selling products.
| Expectation | |
|---|---|
| EPS | $-0.75 |
| Revenue | $14M |
Follow Intellia Therapeutics to get the latest and most important updates.
Follow NTLA